Jounce Therapeutics Inc (NASDAQ:JNCE) CEO Richard /Ca/ Murray sold 16,334 shares of the stock in a transaction that occurred on Thursday, March 8th. The stock was sold at an average price of $25.10, for a total value of $409,983.40. Following the transaction, the chief executive officer now owns 16,334 shares in the company, valued at $409,983.40. The transaction was disclosed in a filing with the SEC, which is accessible through this link.
Richard /Ca/ Murray also recently made the following trade(s):
- On Monday, March 5th, Richard /Ca/ Murray sold 16,334 shares of Jounce Therapeutics stock. The stock was sold at an average price of $21.43, for a total value of $350,037.62.
Shares of Jounce Therapeutics Inc (NASDAQ JNCE) traded up $2.05 during trading hours on Monday, hitting $27.01. The stock had a trading volume of 364,942 shares, compared to its average volume of 364,864. Jounce Therapeutics Inc has a one year low of $11.05 and a one year high of $29.29. The firm has a market capitalization of $870.96 and a price-to-earnings ratio of -50.02.
JNCE has been the topic of a number of research reports. Zacks Investment Research raised Jounce Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 target price on the stock in a research report on Wednesday, January 3rd. JPMorgan Chase & Co. set a $28.00 target price on Jounce Therapeutics and gave the stock a “buy” rating in a research report on Monday, November 13th. Finally, Robert W. Baird set a $35.00 target price on Jounce Therapeutics and gave the stock a “buy” rating in a research report on Thursday.
Several large investors have recently modified their holdings of the company. Teachers Advisors LLC raised its position in shares of Jounce Therapeutics by 26.4% during the second quarter. Teachers Advisors LLC now owns 11,231 shares of the company’s stock worth $158,000 after purchasing an additional 2,347 shares during the period. Alps Advisors Inc. raised its position in Jounce Therapeutics by 12.5% in the 4th quarter. Alps Advisors Inc. now owns 35,642 shares of the company’s stock valued at $454,000 after buying an additional 3,966 shares during the last quarter. Bank of New York Mellon Corp raised its position in Jounce Therapeutics by 10.8% in the 4th quarter. Bank of New York Mellon Corp now owns 45,889 shares of the company’s stock valued at $585,000 after buying an additional 4,467 shares during the last quarter. American International Group Inc. raised its position in Jounce Therapeutics by 132.2% in the 3rd quarter. American International Group Inc. now owns 9,559 shares of the company’s stock valued at $149,000 after buying an additional 5,442 shares during the last quarter. Finally, OxFORD Asset Management LLP raised its position in Jounce Therapeutics by 11.9% in the 3rd quarter. OxFORD Asset Management LLP now owns 59,540 shares of the company’s stock valued at $927,000 after buying an additional 6,328 shares during the last quarter. 90.81% of the stock is currently owned by institutional investors.
Jounce Therapeutics Company Profile
Jounce Therapeutics, Inc is a clinical stage immunotherapy company. The Company is engaged in transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient.
Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.